Morgan Stanley Lowers Bausch Health Companies (NYSE:BHC) Price Target to $32.00

Bausch Health Companies (NYSE:BHC) had its price objective decreased by Morgan Stanley from $34.00 to $32.00 in a research report released on Tuesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.

Several other equities research analysts have also weighed in on the company. Cowen started coverage on Bausch Health Companies in a research note on Friday, October 25th. They set an outperform rating and a $35.00 price objective for the company. JPMorgan Chase & Co. raised Bausch Health Companies from a neutral rating to an overweight rating and raised their price objective for the stock from $32.00 to $38.00 in a research note on Thursday, December 12th. TheStreet raised Bausch Health Companies from a d+ rating to a c rating in a research note on Thursday, December 12th. Wells Fargo & Co raised Bausch Health Companies from an underweight rating to an equal weight rating and set a $32.00 price objective for the company in a research note on Wednesday, January 22nd. Finally, Goldman Sachs Group started coverage on Bausch Health Companies in a research note on Monday, December 2nd. They set a neutral rating and a $30.00 price objective for the company. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $34.06.

BHC opened at $27.74 on Tuesday. The firm has a market cap of $9.67 billion, a PE ratio of 6.38, a P/E/G ratio of 0.57 and a beta of 1.02. The company has a quick ratio of 0.86, a current ratio of 1.15 and a debt-to-equity ratio of 9.17. The business has a fifty day simple moving average of $28.82 and a 200-day simple moving average of $25.51. Bausch Health Companies has a fifty-two week low of $18.72 and a fifty-two week high of $31.97.

Several institutional investors have recently modified their holdings of BHC. Renaissance Technologies LLC boosted its position in shares of Bausch Health Companies by 146.8% in the fourth quarter. Renaissance Technologies LLC now owns 12,491,799 shares of the company’s stock worth $373,769,000 after buying an additional 7,429,396 shares during the period. FMR LLC boosted its position in shares of Bausch Health Companies by 410.9% in the fourth quarter. FMR LLC now owns 1,909,946 shares of the company’s stock worth $57,171,000 after buying an additional 1,536,120 shares during the period. Fiera Capital Corp boosted its position in shares of Bausch Health Companies by 2,337.6% in the fourth quarter. Fiera Capital Corp now owns 1,124,844 shares of the company’s stock worth $33,690,000 after buying an additional 1,078,698 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Bausch Health Companies in the fourth quarter worth $22,440,000. Finally, Lakewood Capital Management LP acquired a new stake in shares of Bausch Health Companies in the fourth quarter worth $20,206,000. 57.38% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.